期刊文献+

SF-36量表在良性前列腺增生症患者生命质量研究中的信度、效度和反应度评价 被引量:7

Assessment of Reliability,Validity and Response of SF-36 in Measuring the Quality of Life of Benign Prostate Hyperplasia Patients
下载PDF
导出
摘要 目的评价SF-36量表在中国良性前列腺增生症患者中的适用性。方法随机抽取确诊的良性前列腺增生症患者219例,患者自填问卷完成SF-36量表,通过统计学检验,评价量表的信度、效度和反应性。结果SF-36量表分半信度0.95,各维度及总表的Cronbachα系数均大于0.7。因子分析产生2个公因子,分别代表生理和心理方面。量表与IPSS症状评分和单条目自感健康相关较好(相关系数分别为-0.54和0.79)。量表能够区分不同年龄、疾病严重程度及治疗前后患者的生命质量。结论SF-36量表适于在中国良性前列腺增生症患者中运用。 Objective To assess the applicability of the SF-36 scales in measuring the quality of life of chinese benign prostate hyperplasia patients. Methods 219 patients selected by random sampling completed SF-36 scales by self-administration.The reliability,validity and response were assessed by statistical tests.Result The split-half reliability of the scales was 0.95,and all of the Cronbach α coefficients were above 0.7.A physical factor and a psychological factor were identified by factor analysis.The scales correlated IPSS symptom grade and single-item perceived-health well(the correlation coefficients were-0.54 and 0.79).The scales could distinguish the QOL of different patients in terms of age,severity of disease and treatment status.The QOL of patients was obviously improved after therapy.Conclusion The SF-36 scales is applicable for measuring the quality of life of chinese benign prostate hyperplasia patients.
出处 《中国社会医学杂志》 2006年第4期221-223,共3页 Chinese Journal of Social Medicine
关键词 SF-36量表 良性前列腺增生症 量表考核 SF-36 scales Benign prostate hyperplasia Psychological tests
  • 相关文献

参考文献8

二级参考文献29

  • 1Fowler FJ Jr,Wennberg JE,Timothy RP,et al.Symptom status and quality of life following prostatectomy[J].JAMA 1988,259(20):3018-3022.
  • 2AUA Practice Guidelines Committee:AUA Guideline on management of Benign Prostatic Hyperplasia(2003).Chapter 1:Diagnosis and treatment recommendations[J].J Urol,2003,170(2):530-547.
  • 3Batista-Miranda JE,Diez MD,Bertran PA,et al.Quality-of-life assessment in patients with benign prostatic hyperplasia:Effects of various interventions [J].Pharmacoeconomics,2001,19(11):1079-1090.
  • 4MacDonagh R,Pearcy R.Quality-of-life aspects in urology-benign prostatic hyperplasia[J].World J Urol,1999,17(4):199-204.
  • 5Jacobsen SJ,Girman CJ,Lieber MM.Natural history of benign prostatic hyperplasia[J].Urology,2001,58(suppl 6A):5-16.
  • 6Kirby RS.The natural history of benign prostatic hyperplasia:What have we learned in the last decade?[J].Urology,2000,56(suppl 5A):3-6.
  • 7de la Rosette JJ,Alivizatos G,Madersbacher S,et al.EAU Guidelines on benign prostatic hyperplasia (BPH)[J].Eur Urol,2001,40(3):256-263.
  • 8Bruskewitz RC,Girman CJ.Effect of finasteride on bother and health-related quality of life associated with benign prostatic hyperplasia[J]. Urology,1999,54(4):670-678.
  • 9Lepor H,Williford WO,Barry MJ,et al.The impact of medical therapy on bother due to symptoms,quality of life and global outcome,and factors predicting response[J].J Urol,1998,160(4):1358-1367.
  • 10Boyle P,Altwein JE,Bartsch G,et al.Patient perceptions of the efffect of medical therapy for bening prostatic hypertrophy in the PREDICT trial [abstract][J].J Urol,1999,161(supp1):266.

共引文献211

同被引文献81

引证文献7

二级引证文献111

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部